Antithrombotic Therapy in Arterial Thrombosis and Thromboembolism in COVID-19

Potpara, Tatjana; Angiolillo, Dominick J.; Bikdeli, Behnood; Capodanno, Davide; Cole, Oana; Yataco, Angel Coz; Dan, Gheorghe-Andrei; Harrison, Stephanie L; Iaccarino, Jonathan M.; Moores, Lisa K.; Ntaios, George; Lip, Gregory Y. H.

doi:10.1016/j.chest.2023.06.032

CHEST

2023

DOI: 10.1016/j.chest.2023.06.032

|View full text |Cite

Antithrombotic Therapy in Arterial Thrombosis and Thromboembolism in COVID-19

Tatjana Potpara¹,

Dominick J. Angiolillo²,

Behnood Bikdeli³

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2023

2024

Publication Types

Select...

Article5

Relationship

Self Cite1

Independent4

Authors

Journals

Cited by 5 publications

(2 citation statements)

References 131 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…disease, has been recognised since early in the pandemic. 1 Guidelines recommend the use of prophylactic anticoagulation in hospitalised patients with COVID-19, [2][3][4] yet despite this, trials report a VTE incidence of 6-10% with prophylactic and 4-8% with treatment-dose anticoagulation. 5,6 Amongst critically-ill patients with COVID-19, 28-46% of patients may experience VTE.…”

mentioning

confidence: 99%

“…The observation that SARS-CoV-2 (severe acute respiratory syndrome coronavirus-2) predisposes patients to pulmonary immunothrombosis and venous thromboembolism (VTE), and furthermore, that the risk of VTE is directly proportional to the severity of coronavirus disease 2019 (COVID- 19) disease has been recognized since early in the pandemic. 1 Guidelines recommend the use of prophylactic anticoagulation in hospitalized patients with COVID-19, [2][3][4] yet despite this, trials report a VTE incidence of 6 to 10% with prophylactic and 4 to 8% with treatment-dose anticoagulation. 5,6 Amongst critically ill patients with COVID-19, 28 to 46% of patients may experience VTE.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Tissue Factor Pathway Inhibitor and Interleukin-1 Receptor Levels in COVID-19

Gorog,

Patel

2024

Thromb Haemost

View full text Add to dashboard Cite

show abstract

mentioning

confidence: 99%

mentioning

confidence: 99%

Tissue Factor Pathway Inhibitor and Interleukin-1 Receptor Levels in COVID-19

Gorog,

Patel

2024

Thromb Haemost

View full text Add to dashboard Cite

show abstract

Low-molecular-weight heparin for the prevention of clinical worsening in severe non-critically ill COVID-19 patients: a joint analysis of two randomized controlled trials

Wu,

Del GIovane,

Colombo

et al. 2023

Intern Emerg Med

View full text Add to dashboard Cite

Impact of prior oral anticoagulation therapies on post‐discharge outcomes after COVID‐19: Results from a global federated health network analysis

Rivera‐Caravaca,

Frost,

Marín

et al. 2024

Eur J Clin Investigation

View full text Add to dashboard Cite

BackgroundThe impact of chronic oral anticoagulant (OACs) use on long‐term post‐discharge outcomes after coronavirus disease 2019 (COVID‐19) hospitalisation remains unclear. Herein, we compared clinical outcomes up to 2‐years after COVID‐19 hospitalisation between patients on vitamin K antagonists (VKAs), direct‐acting OACs (DOACs) and no OAC therapy.MethodsData from TriNetX, a global federated health research network, were used. Adult patients on VKAs, DOACs or no OAC therapy at diagnosis of COVID‐19 between 20 January 2020 and 31 December 2021, who were hospitalised for COVID‐19, were included. The primary outcomes were all‐cause mortality, ischaemic stroke/transient ischaemic attack (TIA)/systemic embolism (SE) and the composite of intracranial haemorrhage (ICH)/gastrointestinal bleeding, at 2 years after COVID‐19 hospitalisation.ResultsWe included 110,834 patients with COVID‐19. Following propensity score matching (PSM), we identified a decreased mortality risk in DOAC‐treated patients compared to the no OAC cohort (RR .808, 95% CI .751–.870). A higher risk of ischaemic stroke/TIA/SE was observed in VKA users compared to DOAC users (RR 1.100, 95% CI 1.020–1.220) and in VKA users compared to patients not taking OAC (RR 1.400, 95% CI 1.140–1.720). VKA use was associated with a greater risk of ICH/gastrointestinal bleeding than DOAC users (RR 1.198, 95% CI 1.066–1.347), while DOAC users had a lower risk compared to no OAC‐treated patients (RR .840, 95% CI .754–.936).ConclusionCOVID‐19 patients taking prior DOACs were associated with lower long‐term mortality risk and ICH/gastrointestinal bleeding than patients not taking OAC. Compared to patients on DOACs, VKA users were associated with higher risks of mortality, ischaemic stroke/TIA/SE and ICH/gastrointestinal bleeding.

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Antithrombotic Therapy in Arterial Thrombosis and Thromboembolism in COVID-19

Cited by 5 publications

References 131 publications

Tissue Factor Pathway Inhibitor and Interleukin-1 Receptor Levels in COVID-19

Tissue Factor Pathway Inhibitor and Interleukin-1 Receptor Levels in COVID-19

Low-molecular-weight heparin for the prevention of clinical worsening in severe non-critically ill COVID-19 patients: a joint analysis of two randomized controlled trials

Impact of prior oral anticoagulation therapies on post‐discharge outcomes after COVID‐19: Results from a global federated health network analysis

Contact Info

Product

Resources

About